She’s lucky she didn’t end up with a case of Limp Lip Seriously though, we’re going to end up with 1920’s Upton Sinclair levels of food fuckery and miraculous snake oils
I’ll sit on my husband’s face in your honor.
Everybody knows the GOP is a shit show. The elephant was just keepin it on brand.
Lihat kiriman asli pada platform media sosial terkait.
Finally… that atrocity of font matching is gone.
Lihat kiriman asli pada platform media sosial terkait.
Quality of life in Tibet improved enormously under Chinese rule. LIfe expectancies rose from 37 to 78. Literacy jumped from the low 30%s to the mid 70%s. Tibetan lay residents owned their own homes for the first time in their nation’s history. The region’s economy expanded rapidly as did the population, thanks to modernizations in transportation, agriculture, and health care. Meanwhile, with the colonial status of Hong Kong at an end and the city incorporated into the general Chinese economy, neighboring Shenzhen has enjoyed a similar economic boom. Residents can move freely into and out of the SEZ in a way they couldn’t under English occupation, they use a common currency rather than relying on conversions to and from British pounds, and they are free from British home rule. Most importantly, the residents are subject to the same taxation and civil rights afforded to the rest of the country - bringing an end to such labor atrocities as the 996 system, tax avoidance, and ecological crimes like illegal fishing and dumping. Given the nightmarish wave of fascist policies currently spilling over the UK, I cannot imagine why anyone would envy living on the other side of the planet while being subjected to a Tommy Robinson inspired government.
Lihat kiriman asli pada platform media sosial terkait.
Protests happening in Iran against the proposed “memorandum of understanding.” I would like to point out two important things. We would agree that these people and their demands represent the revolutionary position of proletarian masses, and as Helyeh Doutaghi pointed out, the nightly protests played a major role in forcing the government to strike in defense of Lebanon last week. She wrote: there has been a noticeable intensification of demands in response to escalating violence against Lebanon over the past week in the streets of Iran. Many carry Hezbollah flags and have been calling for action. In this, pressure emanating from the popular base of the revolution has significantly shaped the posture of the armed forces, particularly amid internal tensions among differing political factions, including reformist elements within Iran. For those still reading: The Islamic Republic of Iran is a democracy and the revolution is ongoing. Its time to retire this orientalist myth of “authoritarian dictatorship” that infects the international subconscious and discourse on Iran You will notice in the protest video above that there are many women, most of whom are in Chador. I have heard from some people who participate in the nightly rallies that less than 5% of the women participants over the last 100 days are with “bad hijab” or no hijab. I would like every single person who reads this to get this into your head: There are many revolutionary women in Iran. And the revolutionary women in Iran are overwhelmingly Pious Believing Muslims. These women are playing a major role in shaping the past present and future of the Islamic Republic and therefore the region (and the planet.) And that hijab, and especially Chador, are inseparable from the anti-imperialist orientation of the Islamic Revolution. Those left/liberals who continue to espouse their Islamophobic tendencies against “Iranian theocracy” and against hijab are positioning themselves in the camp of zionism. End of story.
Lihat kiriman asli pada platform media sosial terkait.
While the October 2024 embed was one of the more preposterous embodiments of Western corporate media’s special relationship with Israel, outlets continue to do a fine job of sanitizing Israeli brutality even when their reporters are not physically viewing the region from inside an Israeli armored vehicle. Since March of this year, Israel has killed at least 3,613 people in Lebanon and displaced 1.2 million, obliterating entire villages and otherwise expanding the ecocidal policy honed in the Gaza Strip. There has been no remotely comparable destruction on the Israeli side, and a recent Reuters article (5/31/26) that had attempted to suggest some symmetry now comes with the preface: “This May 31 story has been corrected to remove a reference to tens of thousands of Israelis being displaced by Hezbollah fire, in paragraph 3.” Like in Gaza, where genocide proceeds apace in spite of a declared ceasefire (FAIR.org, 10/21/25), the media tend to report “ceasefires” in Lebanon without caring to highlight the fact that it’s not a ceasefire when Israel is still pummeling the country and massacring people, all the while setting the stage for a massive land grab with its creeping so-called “evacuation orders.” … As Battah remarked to me, the media’s acceptance and deployment of such arbitrary vocabulary creates “artificial structures” and a sense of orderliness, when in reality “there’s no yellow lines, there’s no yellow, there’s no colors—these are just illegal invasions.” And because media are committed to sanitizing Israel’s behavior rather than questioning it, “colonization becomes normalized.” The eagerness of journalists to do Israel’s bidding is all the more confounding given that Israel is currently the No. 1 killer of journalists in the world. A recent Associated Press article (5/29/26), for example, reduced the pulverization of Lebanon to simply “ongoing fighting in southern Lebanon between Israeli troops and Hezbollah fighters.”
Last Monday, California Reps. Judy Chu, Jimmy Gomez, and Pete Aguilar visited Adelanto Immigration and Customs Enforcement (ICE) Processing Center as the hunger strike in the immigration jail entered its second week. The Democrats met with three of the hunger strikers, who gave them a petition, signed by some 150 people inside the facility, speaking of inhumane conditions inside the jail and degrading treatment by staff. The Adelanto ICE jail is run by private prison company GEO Group. The next day, GEO Group staff entered a unit “in riot gear holding pepper spray, tear gas canisters and zip ties,” and removed two of the people who had met with congressional staff the day before. And on Wednesday, they removed the third person, according to other detainees. Archived at https://web.archive.org/web/20260612121142/https://truthout.org/articles/hunger-strikers-in-adelanto-ice-jail-moved-to-solitary-after-meeting-congressmen/
Bullets: Western drug companies are pouring tens of billions of dollars into China, to develop medicines that can be resold at premium prices in Europe and the United States. China dominates all phases of the pharmaceutical industry, from new drug development, testing, and mass production. Inside China / Business is a reader-supported publication. To receive new posts and support my work, consider becoming a free or paid subscriber. Report: Good morning. Last week the Pentagon blacklisted a group of Chinese companies, including a biotech firm, Wuxi AppTec. That means that US government contracts with Wuxi AppTec are restricted going forward. The Untied States wants to reduce its dependence on China’s pharmaceutical industry, and the Pentagon’s move is a warning to Chinese companies who want access to the $500 billion drug market in the US. The thinking is that Beijing’s dominance in biotech research and drug development will put the United States in the same spot as in for most of the world’s raw materials supply chains, and in rare earth metals and magnets. China’s restrictions on the exports of rare earths means that the Pentagon can’t build advanced weapons platforms, or even replace the missiles and radars that Iran is blowing up in the Persian Gulf, until they can get new mines and refineries online, and then learn how to make the magnets. That’s the background there. In 2025, Wuxi revenues in the American market were 32 billion RMB, which is about $4.7 billion USD. So the US is a major market for Wuxi AppTec; about two thirds of their total sales. But here is the problem on the Americans side: Wuxi helps make a fourth of the drugs and medicines used in the United States, including for the most expensive drugs. Members of Congress are drafting laws, which also target Chinese biotech firms. American drug companies like Pfizer and Bristol Myers are outsourcing research and development work and manufacturing to the Chinese companies, and the Biotech Investment National Security Act would subject those deals to the same high scrutiny they use on Nvidia, for example. Investments in biotechnology will be reviewed by the Treasury Department, and the War Department will assess whether they affect national security. These investments now are enormous, and suddenly so. Pfizer and BMY were two of dozens of companies, which combined for $136 billion worth of licensing deals with Chinese drugmakers. That is a 27 times increase in just five years. Drug companies in the United States and Europe pay Chinese labs to develop the medicines, which are then sold in Western markets with big markups. Naturally that also attracts venture capital money, and VC firms are worried that Congress may harm China’s biotech industry, which will in turn blow up the money-printing machine they’ve got going. They shouldn’t worry about that first part though: It’s already too late to stop Chinese biotech firms. Whether or not they are allowed to license drugs in the US is irrelevant, when they are building drugs for the entire world. The United States is the most lucrative pharmaceutical market, but it’s American and European drug companies who grab most of those profits, along with VC and Private Equity firms who buy up shares in the early-stage drugs. And there are lots of headlines now like this one: drugs developed in China perform better than blockbuster, high-profit drugs on the market in the US. Industry insiders know all that, and the Pentagon blacklisting won’t move the needle at all, on the partnerships between Chinese drug development companies, and the big pharma companies who put their logo on the side of the box and jack up the price a hundred times. China has no peer in building quality compounds at low cost. One issue is keeping all the executives at Western pharma companies awake at night: it’s the patent expirations problem. Morgan Stanley crunched the numbers, and Big Pharma had sales last year of $171 billion from drugs that will go off-patent over the next five years. At Pfizer, it’s an $18 billion problem by 2028, and $20 billion by 2030: (These charts are in billions, not trillions.) Pfizer is PFE, and that $20 billion is about 30% of its total sales, which will be dramatically reduced when those particular drugs go off-patent. At Bristol Myers, BMY, it’s $26 billion in sales that go away, and nearly 60% of its sales. Amgen needs to build new drugs to replace over 60% of their sales. At the moment a drug loses its patent protections, the market opens up to generics from several companies, and the price collapses, along with profit margins. Drug prices fall from 30 to over 80% on average, and the steepest declines are in the American market, because that’s where the prices are set the highest. So Keytruda is a $30 billion drug for Merck, and goes off-patent in 2028 both here and in the United States. And this is why it’s a much bigger problem for them, in the United States: In, Keytruda treatments cost $1,500 to $3,000 dollars each, with a full year cost of $20,000, at the most. In the United States, that’s the cost of a single dose. And a full year of Keytruda treatment costs $150,000 in the United States. Over seven times as much, for the same drug. And your first thought is probably something like, why don’t patients in the United States just fly to China, check into a luxury hotel right next to the hospital, get the treatment there, and fly home and save a hundred thousand dollars? If it’s obvious to us, it’s obvious to Chinese too, and we’ll come back to that. Plus, we’ve just learned that Akeso developed a drug that works better than Keytruda, anyway. Eliquis is a blood-thinner drug used to prevent clots. It comes from Bristol Myers Squibb, and last year threw off over $13 billion in sales. It loses patent protection in 2028 in the United States. In China, Eliquis costs $60 for a 30-day supply. In the US it’s anywhere from 5 to 10 times that depending on the pharmacy the patient is using. Those “patent cliffs” are a major crisis for Big Pharma, but a major opportunity for firms here. China’s biotech companies work faster, with lower costs, and so companies are paying up-front for research to be done here, as soon as possible, to get new drugs ready to sell. Neil Roberts is one of our channel’s compadres, and he’s always sniffing around the internet for stories and angles that are flying under everyone else’s radars. He doesn’t like these deals any more than our Congress does, but for a different reason. His concern is that the Chinese companies may be compromised, by spending their valuable time to develop high-profit-margin drugs for Pfizer and other companies operating in the US market, instead of doing what’s best for everyone else, everywhere else. And that’s valid. We also find it curious that Pfizer donated thousands of dollars to help those two members of Congress get elected, who are now drafting laws to prevent Pfizer from developing new drug pipelines in China. And that Pfizer donated millions of dollars to help President Trump celebrate his election party. And that Pfizer is at the same time sending Chinese labs billions of dollars to make sure they have drugs to sell after 2028. Wuxi Apptec does it all: the R&D, the drug discovery, scientist recruitment and training, and the mass-production. And so there are two points we want to emphasize here, with respect to the Chinese system: the government negotiates hard with drug companies, no matter where from, on fair pricing in exchange for access to China’s population of over a billion patients. But those low prices are even more a function of these Chinese companies’ capability to build and test the drugs, and the capacity to quickly scale up production after approval. Marco Rubio was a Senator in 2024, and reported that the US once enjoyed a comfortable lead in the highest-value research, and China’s biotech industry is now an instrument of “soft power”. The Chinese are selling low-cost drugs to the developing world, and Mr. Rubio—now Secretary of State Rubio—is alarmed. Going back to those math problems we did earlier, the cost differences between China and the United States, for the exact same treatments. Likang is a Chinese company that developed a personalized cancer vaccine. It’s in clinical trials for the FDA; it’s going through the approval process here in China. But the drug is already being offered to patients in Hainan. Very important section, right there. The cost of the treatment will run around $21,000. A similar drug from Merck or Moderna would be multiples of that. This drug may not ever be approved in the US at all, and if so, only at a very high price. So if you’re an American reading that, and maybe your doc has just told you there’s not much they can do for you, what are your options? And it’s on that question that American venture capital and drug companies should be really worried. There is a market for that drug, right now, but China is the only place anyone can get it. Hainan is the world’s largest free-trade zone and is also a giant zone for medical treatments. Over 30 hospitals, offering treatments and therapies that have not yet been approved even here on Mainland China. This will be a multi-trillion dollar industry, for Hainan Island, and for hospitals on the mainland who can offer treatments at a fraction of what hospitals in Europe, or especially in America will charge. Chinese firms developing treatments, and American patients unable to buy them, in the United States; for those patients, those Chinese hospitals are the only ones who can help. Chinese drugmakers will win, either way. Wuxi builds therapies that are in turn sold by American companies, at high profit margins, for the treatment of conditions that are money-no-object from the perspective of patients. These are terminal illnesses, and Wuxi is the only company making the treatments for some of them. Replacing Wuxi in the supply chains means there’s no more coming for years, and remember, American drug companies don’t have “years”. A third of their revenues are going away, starting next year. So the money is pouring in to China to develop new drugs, and soon enough the money will be pouring into China by patients who need treatments that are not even approved in their home countries, or who do the math and figure that it’s like being paid a hundred thousand dollars to take a vacation in Hainan and receive treatment there. This is another company, Hengrui, who is now the top clinical sponsor in the world, with over 400 ongoing clinical trials, and multi-billion-dollar deals with Merck and Glaxo Smith Kline. This did all happen very fast. Just like in everything else, no matter how much our political leadership likes to pretend otherwise. True experts and industry insiders know it. “There is no sense that these are areas the US can win”. Precision medicine, biotech, and medical equipment are literally national-level priorities, national security priorities, for the Chinese government. And while that kind of emphasis would drive prices and costs way up in the American market, like we see at the Pentagon, for example, in China the cost structures go the other way. The system is more efficient, so costs fall, and timelines speed up. Since 2021—and that five-year plan—the number of drugs under development increased eight times. China is committed to excellence in service, and the US is not stepping up and competing, and cannot. Morgan Stanley again, and drugs coming from China will grow to $34 billion in five years, and $220 billion in fifteen years, and a major driver of that increase is that the treatments are for the high-profit-margin drugs. China is investing in the R&D, and in the people and facilities. Zhangjiang Gaoke is in Shanghai, and home to over 1700 medical companies in a single zone. Seed capital investment in US biotech is at the lowest level in over 20 years, so it’s only the Chinese companies now who are doing the hard work of drug research and discovery. Much of that work is very labor-intensive, by highly skilled chemists. So, it’s cost-prohibitive to even try it in San Francisco or Boston. Pudong, Shanghai isn’t cheap, either, but China is where the people are, and those Chinese PhD’s are building the highest-value drugs. China built a new system, while the industry in the United States headed the opposite way. China approved 20,000 new drugs in just two years; in the same time it takes the FDA to look at three hundred or so. And so Chinese companies, and some American ones, are indifferent as to what the Pentagon or Congress does. China is that blue parabola that now is the world leader in new drug discovery and development for the most valuable drugs: China is also that blue line, for Clinical Trial Activity: China is doing more trials than the United States and the EU combined, and there’s a big reason why: Phase I trials take two years in the US but get done in about a third that time in China. In other words, China is doing more trials, and finishing them faster. Here’s another blue line: license-out deals, which tripled from 2024 to 2025. Last year worth $135 billion: And this year, 2026, it’s growing even faster. In the first three months, $60 billion, which is two times the rate of 2025, and 2025 was 10 times bigger than 2021. So that’s the concern on the US side: Western companies are addicted to the low-cost drugs coming out of China, which they can mark up to American patients for hundreds of billions of dollars. But it’s also causing some problems here, for Chinese policymakers, who are concerned in the same way Neil Roberts was in his email to us. The first priority for Chinese drugmakers, should be to care for Chinese patients. Regulators understand that some of these most novel and revolutionary treatments fall far outside the traditional processes for testing and approval. Personalized medicine – precision medicine – is completely different, and millions of patients are suffering, right now. Those patients need faster approvals for those therapies, and they also need companies who will build them. Anew regulatory pathway for treatments for rare and terminal-stage diseases is being established. The objective, specifically, is improved access to the most advanced therapies for Chinese patients. Those new protocols will offer vast new revenue opportunities for Chinese biotech firms, while reducing their need to partner with the Pfizer’s and the Merck’s of the world just to keep the lights on and their people paid. There is massive demand, right now: patients who need new drugs, and need Chinese companies specifically to build them. That new industry will be all-China: all the drug development, and all the treatment, first to Chinese patients, and then to anyone else who buys a plane ticket to Hainan. Be Good. Resources and links: Pentagon casts dark cloud over China biotech https://www.reuters.com/commentary/breakingviews/pentagon-casts-dark-cloud-over-china-biotech-2026-06-09/ Moolenaar, Dingell Introduce Legislation to Prevent Offshoring Biotech Industry to China https://chinaselectcommittee.house.gov/media/press-releases/moolenaar-dingell-introduce-legislation-to-prevent-offshoring-biotech-industry-to-china House bill aims to crack down on China biotech deals https://www.biopharmadive.com/news/binsa-china-biotech-deals-house-moolenaar-dingell/821841/ China’s Biotech Is Cheaper and Faster https://www.nytimes.com/2025/08/17/opinion/china-biotech.html Chinese Company Under Congressional Scrutiny Makes Key U.S. Drugs https://www.nytimes.com/2024/04/15/health/wuxi-us-drugs-congress.html China’s biotech industry sees global expansion as unstoppable, despite US pressure https://www.scmp.com/business/china-business/article/3356778/chinas-biotech-industry-sees-global-expansion-unstoppable-despite-us-pressure Chinese drugmaker becomes top trial sponsor — and other clinical trends https://www.pharmavoice.com/news/chinese-china-drug-clinical-trial-pharma-jiangsu-hengrui/804665/ US drug pricing policies are ‘red lights’ for investors, and China beckons https://www.pharmavoice.com/news/drug-pricing-red-lights-biopharma-china-venture-capital/810167 China turns the tables in biotech https://www.science.org/doi/10.1126/science.aef7757 Patent cliffhanger: will China biotech throw Big Pharma a lifeline? https://www.scmp.com/business/china-business/article/3337038/patent-cliffhanger-will-china-biotech-throw-big-pharma-lifeline Chinese pharmaceutical firms’ cost advantages trump Pentagon blacklist: analysts https://www.scmp.com/business/china-business/article/3356564/chinese-pharmaceutical-firms-cost-advantages-trump-pentagon-blacklist-analysts The paradox of biotech protectionism: Why walling off China biotech weakens America https://rapport.racap.com/all-stories/the-paradox-of-biotech-protectionism-why-walling-off-china-biotech-weakens-america The Innovation Boom in China Biotech https://www.morganstanley.com/insights/articles/china-biotech-boom-generics-to-innovators How China Became the Biotech Industry’s Back-Office https://www.forbes.com/sites/shimiteobialo/2026/01/21/how-china-became-the-biotech-industrys-back-office/ As China biotech crackdown calls reverberate in Washington, the pushback gets louder, too https://www.fiercebiotech.com/biotech/divisive-bill-seeks-add-biotech-industry-law-limiting-investment-chinese-industry The Year China Surpassed the USA in Biotech Innovation, Deal Value, and Clinical Output https://www.synbiobeta.com/read/the-year-china-surpassed-the-usa-in-biotech-innovation-deal-value-and-clinical-output The China question is tearing biotech apart https://www.statnews.com/2026/05/18/biotech-industry-split-chinese-drugs-opportunity-versus-existential-threat/ Amid a flurry of biotech deals, China looks to keep innovation at home https://www.pharmavoice.com/news/licensing-pharma-deal-china-regulation-policy/822443/ Political contributions data from OpenSecrets.org US says BYD, Baidu, Alibaba and other tech giants are aiding China’s military https://www.reuters.com/world/asia-pacific/pentagon-lists-entities-designated-chinese-military-company-2026-06-08/ On this Chinese island, patients are trying latest experimental drugs for cancer https://www.scmp.com/news/china/science/article/3310623/chinese-island-patients-are-trying-latest-experimental-drugs-cancer Inside China / Business is a reader-supported publication. To receive new posts and support my work, consider becoming a free or paid subscriber. From Inside China / Business via This RSS Feed.
A federal judge may have dealt the final blow to President Donald Trump’s $1.8 billion “weaponization fund” on Friday, indefinitely blocking it and ordering his administration to state unequivocally that it’s no longer happening. In the face of bipartisan backlash, acting Attorney General Todd Blanche had publicly backed off plans to use the money earlier this month, and a court temporarily blocked the transfer of the money to what opponents had dubbed a “slush fund” for Trump’s supporters, including January 6 rioters who claim to be victims of government “weaponization” by the Biden administration. But The Atlantic reported on Thursday that even as the US Department of Justice (DOJ) publicly swears that the payouts are dead, administration officials have been reassuring Trump’s cronies behind the scenes that they’ll get their checks and that the administration simply needs to wait for the legal blowback to die down or find an alternative way to award them the money, which was set to follow a DOJ-brokered settlement between Trump and his own Internal Revenue Service (IRS). That may prove more difficult after Friday, however, when US District Judge Leonie M. Brinkema issued a preliminary injunction indefinitely extending her previous two-week pause on the fund. She described the arrangement, to have taxpayer funds disbursed without court rulings to “an extremely small group” that many Americans feel engaged in “unacceptable” conduct, as “problematic.” The DOJ had attempted to have the case against the fund dismissed, arguing that it was now a moot point, since Blanche had publicly declared it dead. But Brinkema said, "The [government’s] mootness argument, in my view, doesn’t go anywhere.” While the DOJ stated that the fund has “not been set up and is now not going forward," Brinkema noted that Blanche had declined to state that under oath, while Trump has publicly continued to champion the fund even as his administration has backed away from it. During the hearing in the Eastern District of Virginia, Brinkema pressed DOJ lawyer Andrew Block on why, if the fund was truly defunct, the administration had not formally rescinded the order setting it up. He said he didn’t know. The judge gave Blanche, Associate Attorney General Stanley Woodward Jr., and Treasury Secretary Scott Bessent, whose department would have overseen the fund, one week to sign a “clear, unambiguous” declaration stating under penalty of perjury that the fund is dead, and wrote in the order that they must affirm that it “will not proceed in any manner, or under any name.” She said in order for the lawsuit to be thrown out, the government needed to put it in writing because “we don’t have the kind of absolute certainty that this fund wouldn’t rear its head.” CEO @SkyePerryman and Senior Counsel Pooja Boisture break down our major slush fund win from court. pic.twitter.com/ngneLRsl8R — Democracy Forward (@DemocracyFwd) June 12, 2026 Outside the courtroom, Skye Perryman, the president and CEO of Democracy Forward—the watchdog group that sued the DOJ—celebrated that the court had “put the brakes on Donald Trump’s slush fund.” The group is representing several plaintiffs who say they’d be harmed if the fund were to be enacted. They include a former federal prosecutor fired after leading January 6 cases; the city of New Haven, Connecticut, which has been targeted by the administration over its sanctuary policies; the National Abortion Federation, which says the fund could reward anti-abortion activists convicted of clinic-related offenses; and the watchdog group Common Cause, which argues that the opaque scheme could embolden January 6 defendants. “We were thrilled that the judge understood the significant harm that our clients face as a result of the fund, as well as the American people,” said Democracy Forward senior counsel Pooja Boisture. “We were thrilled that she got it right. She understood that this was not a partisan issue.” It remains unclear whether the order would stop the administration from pursuing other methods for rewarding Trump’s allies. Reuters reported on Friday that his legal allies have discussed dusting off a 1946 law called the Federal Tort Claims Act, which would allow individuals to file administrative claims and lawsuits that could be settled out of court with a lot of flexibility for the government. “The Trump administration cannot be trusted with the public’s money,” said Omar Noureldin, Common Cause’s senior vice president for policy and litigation. "We’ve successfully locked the president’s personal slush fund for now, and we’ll keep the pressure on until it’s shut down for good.” From Common Dreams via This RSS Feed.
This is an appeal to forgive literal convicted terrorists that came up in my social media feed. Is this China redirecting the “free east turkistan” wave to show people “east turkistan” is a terrorist movement or are the CIA/NGO trolls just that out of touch with reality? The fact that the image includes the aftermath of their terrorist bombing makes me think this is China, and its really clever.
Lihat kiriman asli pada platform media sosial terkait.
Found an adorable pair. Baby is under mom in the first pic but I got one of them both escaping my gaze.
Lihat kiriman asli pada platform media sosial terkait.
cross-posted from: https://lemmy.world/post/48092091 Part 2 of 4. Part 1 here : • Harvesting Rainwater with Brad Lancaster: … In this second video showcasing Brad Lancaster’s work in Tucson, we check out a large Guerrilla Planting project as well as more of the rainwater catchment projects on the neighborhood streets. For more on Brad and his community’s work: • Subscribe to his YouTube channel: youtube.com/c/HarvestingRainwater • Check out his “Rainwater Harvesting for Drylands & Beyond” books and website: www.harvestingrainwater.com/ • Check out his community’s rain-irrigated native food forestry website: dunbarspringneighborhoodforesters.org/ Your contributions support this content. It sounds cliché but it’s true. Whether it’s travel expenses, vehicle repair, or medical costs for urushiol poisoning (or rockfalls, bee-stings, hand slices, toxic sap, etc), your financial support allows this content to continue so the beauty of Earth’s flora can be made accessible to the public, accompanied by a small dose of profanity and crude humor. At a time when so much is disappearing beneath the human footprint, CPBBD is willing to do whatever it takes to document these plant species and the ecological communities they are a part of before they’re gone for good. Plants make people feel good. Plants quell homicidal (and suicidal!) thoughts. To support Crime Pays But Botany Doesn’t, consider donating a few bucks to the venmo account “societyishell” or the PayPal account email [email protected]… Or consider becoming a patreon supporter @ : www.patreon.com/CrimePaysButBotanyDoesnt Buy some CPBBD merch (shirts, hats, hoodies n’ what the shit) available for sale at : www.bonfire.com/store/crime-pays-but-botany-doesnt… To purchase stickers, venmo 20 bucks to “societyishell” and leave your address in the comments. Plants ID questions or reading list suggestions can be sent to [email protected] Thanks, GFY.
Obama’s ACA That was 15 years ago. You’re going to coast on a less generous Heritage Foundation policy forever as long as you get the genocide you and every other centrist has always wanted.
IT pro | Generic white dude | probably high.
I’m not ignoring societal pressures, but at some point you have to take responsibility for your priorities. I assume you wouldn’t excuse billionaires as just participating in capitalism and doing what they’re “supposed” to do. The harm of invasive medical procedures and medications for aesthetic reasons seems like a good place to draw the line and say “you have a problem”
Lihat kiriman asli pada platform media sosial terkait.
I do plan on running some emulation tests eventually, the only problem with this laptop is it’s got 1 usb 2.0, 1 3.0 and type c ports, and my xbox pad is usb and those two slots are being occupied by a kb and mouse.
Just a dumb guy fighting entropy
Well one is the cessation of slaughter, the other is a reduction of slaughter. Bit of a qualitative difference. Unless you think that the U.S. is just going to start going in and killing random Venezuelans again. Which, they might, if they actually get a base up and running, but that hasn’t actually happened yet. Could, but hasn’t. And then I will not be glad.
Lihat kiriman asli pada platform media sosial terkait.
AntiX Linux has been the most efficient distro on my netbook. You gotta be okay without systemd though. For the most part I didn’t need it but some things are highly dependent on systemd to work. WattOS was good too but AFAIK it’s not actually open source so I couldn’t trust it.
'We are in a race between education and oblivion" -R B Fuller
Google managed to displace almost the entire GNU userland from Android before Android even shipped. The transition happened between 2005–2008, meaning it took roughly 3 years from Google acquiring Android Inc. to releasing a much more competent OS that used Linux but not GNU. GNU Hurd just recently got over their 64bit hurdle that every other OS seemed to fly over.Everyone else is building for the future. GNU is still optimizing for hardware that died before MySpace. GNU Coreutils vs. Rust Rewrites (uutils, ripgrep, fd, bat, exa/eza). The Rust rewrites are faster, safer, and more portable. GNU coreutils is the reason people think ls needs 40 flags. Rust rewrites prove it doesn’t. GNU Bash is the default but not the best. fish has sane defaults and human-readable syntax. nushell has structured data pipelines. zsh has better completion and interactivity. oil shell is a modernized POSIX shell with real error handling. FSF governance is slow and insular. Modern projects use open governance (Rust, Kubernetes, LLVM). Copyleft 3 licensing scared off industry adoption. GNU projects often reject modernization on ideological grounds. (GNU/Linux holds itself back, while LiGNUxers think they can fix it by recruiting more LiGNUxers).